ADCC, CDC, and ADCP Assay Services

We have the experience and expertise to provide complete ADCC/CDC/ADCP testing solutions.

ADCC, CDC, and ADCP are critical immune mechanisms that underlie the success of antibody-based therapies. Each of these mechanisms operates through distinct immune components but shares the goal of eliminating pathogenic or malignant cells. Creative Biolabs leverages its advanced technology platforms and extensive expertise to provide ADCC/CDC/ADCP levels detection services, helping you optimize antibody designs and give guidance on enhancing these effector functions for more effective therapies. Based on state-of-the-art laboratories, we can ensure the efficacy and potency of your therapeutic antibodies by implementing strict QC standards.

Get an Instant Quote →

Fig.1 Fc-mediated Effector Functions.¹

ADCC/CDC/ADCP in Antibody Development

Optimizing Antibody Therapeutic Efficacy

By measuring the levels of these activities during antibody discovery, researchers can assess and enhance the potential of therapeutic antibodies to elicit robust immune responses against target cells

Fine-tuning Antibody Design

Not all antibodies are designed to activate all three mechanisms (ADCC, CDC, ADCP). Some therapeutic strategies may prioritize one over the others, depending on the target disease and the desired immune response

Safety and Off-target Effects

Detecting these levels allows for a better understanding of the potential risks of non-specific immune activation.

Predicting Clinical Performance

The levels of ADCC, CDC, and ADCP detected during the discovery and development phases can serve as predictors of the clinical performance of the therapeutic antibody.

Regulatory and Quality Control

Accurate measurement of ADCC, CDC, and ADCP levels is important for meeting regulatory standards during the antibody development process.

Key Features of ADCC/CDC/ADCP

Antibody-dependent cellular cytotoxicity (ADCC)

In antibody-dependent cellular cytotoxicity (ADCC), the Fcγ receptor (FcγR or FCGR) on immune effector cells binds to the Fc region of an antibody, which is attached to a specific target cell. Immune cells like natural killer cells, macrophages, monocytes, and eosinophils can mediate ADCC. Once FCGR engages with the antibody, its ITAM domain is phosphorylated, leading to effector cell activation. This activation triggers the release of substances such as perforin, granzyme, lyase, and TNF, which contribute to the targeted cell’s destruction. At Creative Biolabs, our team of scientists has extensive experience in PBMC-mediated ADCC assay that is designed to accurately assess ADCC activity.

Complement-dependent cytotoxicity (CDC)

In complement-dependent cytotoxicity (CDC), C1q binds to antibodies, which triggers the complement cascade, resulting in the formation of a membrane attack complex (MAC) (C5b to C9) on the surface of target cells, and further resulting in a classical pathway of complement activation.

Antibody-dependent cellular phagocytosis (ADCP)

Antibody-dependent cellular phagocytosis (ADCP) is a key MOA for many antibody-based therapies. It is defined as a highly regulated process in which an antibody eliminates binding target and initiates phagocytosis by linking its Fc domain to a specific receptor on the phagocytic cell. Unlike ADCC, ADCP can mediate monocytes, macrophages, neutrophils and dendritic cells via FcγRIIa, FcγRI and FcγRIIIa, where FcγRIIa (CD32a) on macrophages represents the major pathway. To meet this need, Creative Biolabs has launched a primary cell-based ADCP assay service.

Tab.1 Key Differences of ADCC/CDC/ADCP

Get Your Tailored Solutions